The global knee replacement surgery market is projected to reach $16.17 billion by 2030, expanding at a 6.1% compound annual growth rate from its 2025 value of $12 billion. This growth is fueled by an aging global population, the rising prevalence of osteoarthritis, and the increasing adoption of advanced surgical technologies.
The projected market expansion reflects a confluence of demographic and technological trends. An increasingly older population, coupled with a higher incidence of age-related joint disorders, creates substantial demand for knee replacement procedures. This growth trajectory presents opportunities for device manufacturers, surgical centers, and technology providers, but also raises questions about workforce capacity and healthcare system preparedness.
The cost of these procedures, particularly in emerging markets with limited insurance coverage, remains a significant barrier to widespread access. However, technological innovations like robotic-assisted surgery, 3D-printed implants, and personalized surgical planning offer opportunities to improve outcomes and potentially reduce costs in the long run. These advances, while promising, also necessitate specialized training and infrastructure investment, which creates challenges for their adoption and implementation.
The anticipated market growth is expected to disproportionately benefit hospitals and surgical centers, particularly in North America, where higher disease prevalence and increased access to minimally invasive procedures drive demand. The increasing burden of osteoporosis-related fractures further underscores the need for scalable and cost-effective solutions. This geographic concentration of demand creates strategic advantages for established players with robust distribution networks and regulatory expertise.
The projected growth also highlights an impending workforce shortage. A dwindling supply of skilled orthopedic surgeons, coupled with the complex training required for advanced surgical techniques, may constrain market expansion. Addressing this gap will require strategic investments in training programs, workforce development initiatives, and potentially task-shifting models of care. The long-term sustainability of this market depends on effectively navigating the tension between increasing demand, technological advancements, and workforce limitations.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
